- Home
- PLUR vs INTS Comparison
PLUR vs INTS Comparison
Compare PLUR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- INTS
- Stock Information
- Founded
- PLUR 2001
- INTS 2012
- Country
- PLUR Israel
- INTS United States
- Employees
- PLUR N/A
- INTS N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- INTS Health Care
- Exchange
- PLUR Nasdaq
- INTS Nasdaq
- Market Cap
- PLUR 26.7M
- INTS 30.8M
- IPO Year
- PLUR N/A
- INTS 2023
- Fundamental
- Price
- PLUR $6.75
- INTS $1.30
- Analyst Decision
- PLUR
- INTS Strong Buy
- Analyst Count
- PLUR 0
- INTS 3
- Target Price
- PLUR N/A
- INTS $8.50
- AVG Volume (30 Days)
- PLUR 24.8K
- INTS 37.8K
- Earning Date
- PLUR 05-09-2025
- INTS 05-08-2025
- Dividend Yield
- PLUR N/A
- INTS N/A
- EPS Growth
- PLUR N/A
- INTS N/A
- EPS
- PLUR N/A
- INTS N/A
- Revenue
- PLUR $678,000.00
- INTS N/A
- Revenue This Year
- PLUR $472.39
- INTS N/A
- Revenue Next Year
- PLUR $254.29
- INTS N/A
- P/E Ratio
- PLUR N/A
- INTS N/A
- Revenue Growth
- PLUR 89.92
- INTS N/A
- 52 Week Low
- PLUR $3.33
- INTS $1.27
- 52 Week High
- PLUR $6.60
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- PLUR 80.65
- INTS 22.77
- Support Level
- PLUR $3.36
- INTS $1.78
- Resistance Level
- PLUR $3.92
- INTS $1.94
- Average True Range (ATR)
- PLUR 0.48
- INTS 0.17
- MACD
- PLUR 0.24
- INTS -0.03
- Stochastic Oscillator
- PLUR 90.00
- INTS 4.10
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.